FIELD: pharmaceutics.
SUBSTANCE: group of inventions relates to pharmaceutical industry, namely to monolithic implantation subcutaneous drug delivery system and its use in a method for the treatment and prevention of HIV infection. Monolithic implantation subcutaneous drug delivery system includes ethylene-vinyl acetate copolymer and 4'-ethynyl-2-fluoro-2'-deoxyadenosine, where 4'-ethynyl-2-fluoro-2'-deoxyadenosine is continuously released in vivo at a rate leading to the concentration in plasma in the range from 0.02 ng/ml to 300.0 ng/ml. A method for the treatment or prevention of HIV infection using implantation drug delivery system is also proposed.
EFFECT: above-described solution provides for continuous release of 4'-ethynyl-2-fluoro-2'-deoxyadenosine in vivo for a long time.
14 cl, 1 dwg, 11 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| X-RAY VISIBLE DRUG DELIVERY DEVICE | 2005 |
|
RU2384347C2 |
| 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AND PRODUCTION THEREOF | 2016 |
|
RU2720811C2 |
| INTRAOCULAR DRUG DELIVERY SYSTEMS | 2007 |
|
RU2440102C2 |
| SYSTEM OF MEDICATION DELIVERY | 2008 |
|
RU2488369C2 |
| ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 2020 |
|
RU2824528C2 |
| RESIN COMPOSITION FOR LEUPROLIDE DELIVERY OF IMPROVED EFFECTIVENESS | 2001 |
|
RU2271826C2 |
| INTRAVAGINAL DEVICE FOR DRUG DELIVERY | 2012 |
|
RU2607179C2 |
| BIODEGRADABLE DRUG DELIVERY SYSTEMS FOR LONG-TERM RELEASE OF PROTEIN | 2013 |
|
RU2676102C2 |
| INTRAOCULAR SYSTEMS OF SUSTAINED-RELEASE DRUG DELIVERY AND METHOD OF TREATING OPHTHALMIC DISEASES | 2010 |
|
RU2532333C2 |
| DRUG DELIVERY SYSTEM | 2002 |
|
RU2302883C2 |
